期刊
CELL METABOLISM
卷 7, 期 2, 页码 125-134出版社
CELL PRESS
DOI: 10.1016/j.cmet.2007.11.013
关键词
-
资金
- NHLBI NIH HHS [HL55368, HL73030, R01 HL073030] Funding Source: Medline
- NIDDK NIH HHS [R37 DK031036, DK036588, R01 DK045935, R01 DK031036, R01 DK075850, DK053105, DK59637-01, R01 DK036588, R01 DK056626, R37 DK036588, DK45935, U24 DK059637, K12 DK063696, R01 DK048873, R01 DK053105, R01 DK073687, DK75850, DK073687, DK31036, P30 DK36836, R37 DK048873, P30 DK036836, K08DK073358] Funding Source: Medline
Insulin resistance plays a central role in the development of the metabolic syndrome, but how it relates to cardiovascular disease remains controversial. Liver insulin receptor knockout (LIRKO) mice have pure hepatic insulin resistance. On a standard chow diet, LIRKO mice have a proatherogenic lipoprotein profile with reduced high-density lipoprotein (HDL) cholesterol and very low-density lipoprotein (VLDL) particles that are markedly enriched in cholesterol. This is due to increased secretion and decreased clearance of apolipoprotein B-containing lipoproteins, coupled with decreased triglyceride secretion secondary to increased expression of Pgc-1 beta (Ppargc-1b), which promotes VLDL secretion, but decreased expression of Srebp-1c (Srebf1), Srebp-2 (Srebf2), and their targets, the lipogenic enzymes and the LDL receptor. Within 12 weeks on an atherogenic diet, LIRKO mice show marked hypercholesterolemia, and 100% of LIRKO mice, but 0% of controls, develop severe atherosclerosis. Thus, insulin resistance at the level of the liver is sufficient to produce the dyslipidemia and increased risk of atherosclerosis associated with the metabolic syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据